

immediately after EC use so that we can give women evidence-based advice on how long additional precautions are needed after EC before they can rely exclusively on their chosen contraceptive method.

#### Statements on funding and competing interests

**Funding** Both authors have been study investigators on a study comparing ulipristal acetate and levonorgestrel, funded by HRA Pharma.

**Competing interests.** None identified.

#### References

- Mansour D. ellaOne®: a second-generation emergency contraceptive? *J Fam Plann Reprod Health Care* 2009; **35**: 217–218.
- Croxatto HB, Brache V, Cochon L, Jesam C, Salvatierra AM, Levy D, *et al.* The effects of immediate pre-ovulatory administration of 30 mg ulipristal acetate on follicular rupture. Abstract presented at the 8th Congress of the European Society of Gynecology, Rome, Italy, 10–13 September 2009.
- Croxatto HB, Brache V, Pavez M, Cochon L, Forcelledo ML, Alvarez F, *et al.* Pituitary–ovarian function following the standard levonorgestrel emergency contraceptive dose or a single 0.75-mg dose given on the days preceding ovulation. *Contraception* 2004; **70**: 442–450.
- Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M, *et al.* Progesterone receptor modulator for emergency contraception: a randomized controlled trial. *Obstet Gynecol* 2006; **108**: 1089–1097.
- Cameron S, Glasier A, Fine P, Mathe H, Gainer E. Ulipristal acetate compared to levonorgestrel for emergency contraception within five days of unprotected intercourse: a randomised controlled trial. Abstract presented at the 8th Congress of the European Society of Gynecology, Rome, Italy, 10–13 September 2009.
- Ulmann A, Scherrer B, Mathe H, Gainer E, HRA Pharma. Meta-analysis demonstrating superiority of the selective progesterone receptor modulator ulipristal acetate versus levonorgestrel for emergency contraception. Abstract and poster presented at the 8th Congress of the European Society of Gynecology, Rome, Italy, 10–13 September 2009.
- Marston C, Meltzer H, Majeed A. Impact on contraceptive practice of making emergency contraception available over the counter in Great Britain: repeated cross sectional surveys. *BMJ* 2005; **331**: 271.
- Cheng L, Gülmezoglu AM, Piaggio G, Ezcurra E, Van Look PF. Interventions for emergency contraception. *Cochrane Database Syst Rev* 2008; **2**: CD001324.
- Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance (April 2006). Emergency contraception. *J Fam Plann Reprod Health Care* 2006; **32**: 121–128. [http://www.ffprhc.org.uk/admin/uploads/449\\_EmergencyContraceptionCEUGuidance.pdf](http://www.ffprhc.org.uk/admin/uploads/449_EmergencyContraceptionCEUGuidance.pdf) [Accessed 1 December 2009].
- Glasier A, Gebbie A (eds). *Handbook of Family Planning and Reproductive Healthcare* (5th edn). London, UK: Churchill, 2007; 191–200.
- HRA Pharma UK Limited. ellaOne 30 mg: Summary of Product Characteristics. 2009. <http://emc.medicines.org.uk/medicine/22280/SPC/ellaOne+30+mg/> [Accessed 1 December 2009].
- Pharmacists are to offer the pill in London pilot scheme. *BMJ* 2008; **337**: a3016.



## NEW DOCUMENTS ON FACULTY WEBSITE

([www.fsrh.org](http://www.fsrh.org))

### Clinical Effectiveness Unit (CEU) Statements

#### **Ulipristal Acetate (EllaOne®) Emergency Contraception**

The CEU has produced a list of 'Frequently Asked Questions' that is intended as a quick reference guide to the use of ulipristal acetate in UK clinical practice. This document supplements the CEU's New Product Review of ulipristal acetate (October 2009).

#### **Anticonvulsant Therapy and Contraception**

A Faculty Statement on 'Anticonvulsant Therapy and Contraception' will soon be published. The Statement includes guidance from the Medicines and Healthcare Regulatory Agency, new medical eligibility criteria (UKMEC 2009) and new data on lamotrigine interactions. This document supersedes the Faculty Statement on 'Changes to Prescribing Information for Lamotrigine' (2005).

Enquiries/feedback to: Janice Paterson, CEU Administrator, Clinical Effectiveness Unit, Sandyford, 2/6 Sandyford Place, Glasgow G3 7NB, UK. Tel: +44 (0) 141 232 8459. E-mail: [ceu.members@ggc.scot.nhs.uk](mailto:ceu.members@ggc.scot.nhs.uk)

### UK Medical Eligibility Criteria for Contraceptive Use (UKMEC) 2009 Edition

The pdf version of UKMEC 2009, together with summary sheets and a summary of changes, are now available on the Faculty website. Printed copies of the publication are to be distributed to all general practices, sexual health and GUM clinics in the UK in early 2010.

**NB. Paper copies are NOT AVAILABLE IN ADVANCE of this distribution.**



## FSRH CLINICAL EFFECTIVENESS UNIT

### Local Coordinators for Audit of vLARC Continuation Rates



The Clinical Effectiveness Unit (CEU) would like to hear from any doctor or nurse interested in acting as local coordinator for a national, multicentre audit of very Long-Acting Reversible Contraception (vLARC) continuation rates. Services providing implants and intrauterine methods (including abortion providers) will be eligible to take part. The local coordinator will be responsible for facilitating recruitment and returning baseline questionnaires to the CEU over a short period of time. All other administrative work and follow-up will be undertaken by the CEU. Please contact Dr Susanna Hall, CEU research doctor, for further information. Tel: +44 (0) 141 232 8450 or e-mail: [ceu.members@ggc.scot.nhs.uk](mailto:ceu.members@ggc.scot.nhs.uk)